Relaxin-2 Does Not Ameliorate Nephropathy in an Experimental Model of Type-1 Diabetes

• Main Authors: Thomas Bernd Dschietzig (Author), Katharina Krause-Relle (Author), Maud Hennequin (Author), Karoline von Websky (Author), Jan Rahnenführer (Author), Jana Ruppert (Author), Hans Jürgen Grön (Author), Franz Paul Armbruster (Author), Ross A. D. Bathgate (Author), Joerg R. Aschenbach (Author), Wolf-Georg Forssmann (Author), Berthold Hocher (Author)
• Format: Book
• Published: Karger Publishers, 2015-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background/Aims: In diabetic nephropathy (DN), the current angiotensin-II-blocking pharmacotherapy is frequently failing. For diabetic cardiomyopathy (DC), there is no specific remedy available. Relaxin-2 (Rlx) - an anti-fibrotic, anti-inflammatory, and vasoprotecting peptide - is a candidate drug f...